McKesson Corp
MCK: XNYS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| $174.00 | Vdrkdr | Hvxxbsln |
McKesson's Near-Term Looks Promising on OptumRx Win, GLP-1 Tailwinds, and Specialty Solutions
/s3.amazonaws.com/arc-authors/morningstar/b76d1412-e5af-4b94-8222-8cb66fe23dbe.jpg)
Business Strategy and Outlook
McKesson is one of three leading domestic wholesalers of branded, generic, and specialty pharmaceutical products. With roughly $280 billion in sales from its US pharmaceutical segment in fiscal 2024, the company supplies roughly one third of the domestic drug distribution market. Its two close competitors are Cencora and Cardinal Health. Together, the three operate as a pharmaceutical wholesale and distribution oligopoly, supplying over 90% of the US market.